Tislelizumab
BGB-LC-202
Phase 3 small_molecule active
Quick answer
Tislelizumab for Non Small Cell Lung Cancer is a Phase 3 program (small_molecule) at BeOne Medicines with 4 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- Non Small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active